PMID- 16487695
OWN - NLM
STAT- MEDLINE
DCOM- 20070612
LR  - 20220408
IS  - 0954-6111 (Print)
IS  - 0954-6111 (Linking)
VI  - 100
IP  - 9
DP  - 2006 Sep
TI  - Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in 
      combination with tobramycin, administered every 6 h for treatment of nosocomial 
      pneumonia.
PG  - 1554-65
AB  - This randomized, double-blind, multicenter study compared the efficacy and safety 
      of piperacillin/tazobactam (P/T) and imipenem/cilastatin (IMP), both in 
      combination with an aminoglycoside, in hospitalized patients with acute 
      nosocomial pneumonia (NP). Patients with acute NP, defined as pneumonia with 
      symptoms > or = 48 h after admission or < or =7 days after hospital discharge, 
      received infusions of 4 g/500 mg P/T or 500 mg/500 mg IMP every 6 h. Endpoints 
      were clinical cure and microbiological response rates; pathogen eradication 
      rates; length of hospital stay; hospital readmissions; and adverse events (AEs). 
      Of 437 patients in the intent-to-treat population, 197 were efficacy evaluable. 
      At test-of-cure, response rates were similar between groups. Within the efficacy 
      evaluable population, 68% of P/T patients and 61% of IMP patients were clinically 
      cured (P = 0.256). Microbiological responses for P/T and IMP patients were: 
      eradication, 64% versus 59%; persistence, 29% versus 21%; relapse, 0% versus 5%; 
      and superinfection, 7% versus 15%, respectively. Gram-positive isolates were 
      eradicated in 83% of P/T patients and 75% of IMP patients; Gram-negative 
      pathogens were eradicated in 72% of P/T patients and 77% of IMP patients. 
      Treatment groups had similar number of mean hospital days, readmission rates, and 
      frequency of AEs. This study showed that P/T administered four times per day was 
      as safe and efficacious as IMP in treating hospitalized patients with NP.
FAU - Joshi, Manjari
AU  - Joshi M
AD  - University of Maryland School of Medicine, R Adams Cowley Shock Trauma Center, 
      Baltimore, MD 21201, USA. manjari03@aol.com
FAU - Metzler, Michael
AU  - Metzler M
FAU - McCarthy, Mary
AU  - McCarthy M
FAU - Olvey, Stephen
AU  - Olvey S
FAU - Kassira, Wedad
AU  - Kassira W
FAU - Cooper, Angel
AU  - Cooper A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060217
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Protease Inhibitors)
RN  - 141A6AMN38 (Cilastatin)
RN  - 71OTZ9ZE0A (Imipenem)
RN  - 87-53-6 (Penicillanic Acid)
RN  - SE10G96M8W (Tazobactam)
RN  - VZ8RRZ51VK (Tobramycin)
RN  - X00B0D5O0E (Piperacillin)
SB  - IM
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Cilastatin/administration & dosage
MH  - Cross Infection/drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Enzyme Inhibitors/administration & dosage
MH  - Female
MH  - Humans
MH  - Imipenem/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Penicillanic Acid/administration & dosage/analogs & derivatives
MH  - Piperacillin/administration & dosage
MH  - Pneumonia, Ventilator-Associated/*drug therapy
MH  - Protease Inhibitors/administration & dosage
MH  - Tazobactam
MH  - Tobramycin/administration & dosage
MH  - Treatment Outcome
EDAT- 2006/02/21 09:00
MHDA- 2007/06/15 09:00
CRDT- 2006/02/21 09:00
PHST- 2004/08/02 00:00 [received]
PHST- 2005/09/27 00:00 [revised]
PHST- 2006/01/05 00:00 [accepted]
PHST- 2006/02/21 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2006/02/21 09:00 [entrez]
AID - S0954-6111(06)00011-4 [pii]
AID - 10.1016/j.rmed.2006.01.004 [doi]
PST - ppublish
SO  - Respir Med. 2006 Sep;100(9):1554-65. doi: 10.1016/j.rmed.2006.01.004. Epub 2006 
      Feb 17.